A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Myeloid Therapeutics
Jonsson Comprehensive Cancer Center
Seagen Inc.
West China Hospital
Incyte Corporation
Actym Therapeutics, Inc.
Elicio Therapeutics
Jonsson Comprehensive Cancer Center
Toray Industries, Inc
University Hospital, Ghent
NextPoint Therapeutics, Inc.
Zymeworks BC Inc.
Symphogen A/S
NGM Biopharmaceuticals, Inc
ABM Therapeutics Corporation
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Celon Pharma SA
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
AbbVie
AstraZeneca